Haleon (HLN)

Haleon plc (NYSE:HLN ) Q1 2025 Results Conference Call April 30, 2025 3:30 PM ET Company Participants Jo Russell - Head-Investor Relations Dawn Allen - Chief Financial Officer Conference Call Particip...

Haleon on Thursday raised its medium-term target for profit growth from 2026, banking on strength in key markets and costs cuts within its supply chain, which would save the consumer healthcare group ...

Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 1% after the toothpaste and painkillers maker reported slightly stronger first-quarter growth than expected but saw a weaker performance than expected from i...

British consumer healthcare group Haleon on Wednesday reported a 2.3% fall in its first-quarter revenue as sluggish demand for its cold and cough medicines outside of North America continued to weigh.

British consumer healthcare group Haleon said on Tuesday it has gained complete ownership of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake for about 1.62 bil...

Citi believes Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, describing the consumer healthcare group as a solid defensive play for investors concerned about rece...

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margin...

Haleon PLC (LSE:HLN, NYSE:HLN) has bought roughly £170 million of its shares back from former parent company Pfizer Inc (NYSE:PFE, ETR:PFE).   The FTSE 100-listed maker of toothpaste and vitamins paid...

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for t...

Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.